PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

GlobeNewswire

REGULATED INFORMATION

GHENT, Belgium, 30 September 2013 - Ablynx [Euronext Brussels: ABLX], today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Biotech Value Fund Partners LP (BVF Partners LP) and Biotech Value Fund Inc (BVF Inc).

The above shareholders notified that they have exceeded the 3% threshold and now hold 1,704,621 Ablynx shares, which represent 3.49% of the current 48,802,115 outstanding shares of Ablynx.

As the general partner of Biotechnology Value Fund LP (BVF) and Biotech Value Fund II LP (BVF 2), BVF Partners LP (Partners) is authorised to exercise the voting rights owned directly by BVF and BVF 2. As the advisor to Investment 10, LLC (INV 10) and the manager of BVF Investments, LLC (BVF LLC) BVF Partners is authorised to exercise the voting rights owned directly by INV10 and BVF LLC. As the general partner of BVF Partners, BVF Inc has management authority over BFV Partners. As the President of BFV Inc, Mr Lampert has management authority over BFV Inc.

Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and six Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t:   +44 207 920 2345
e:  ablynx@consilium-comms.com

press release in pdf format



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE

HUG#1732462
View Comments (0)